Publikasi Scopus FKUI 2021 per tanggal 31 Mei 2021 (358 artikel)

Silalahi T., Alwi I., Suyatna F., Sartika K.D.
56275255400;15055173800;57218261563;57221849323;
Curcumin's Effect on Inflammatory Response following Percutaneous Coronary Intervention in Adult Patients with Stable Coronary Heart Disease
2021
International Journal of Angiology
Division of Cardiovascular, Department of Internal Medicine, Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Division Cardiovascular, Department of Internal Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Clinical Pharmacology, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
Silalahi, T., Division of Cardiovascular, Department of Internal Medicine, Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Alwi, I., Division Cardiovascular, Department of Internal Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Suyatna, F., Department of Clinical Pharmacology, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Sartika, K.D., Division of Cardiovascular, Department of Internal Medicine, Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
Cardiovascular diseases play major roles in the health problems worldwide especially in Indonesia. Percutaneous coronary intervention (PCI) is a minimally invasive procedure with relatively low complications. However, high inflammatory response post-PCI has showed adverse events even after administration of standard medication. Previous studies showed that curcumin was able to reduce inflammatory response in adult patients with stable coronary heart disease (CHD). This article determines the efficacy of oral administration of curcumin in reducing inflammatory response post-PCI with stable CHD. A double-blind randomized controlled trial on 50 adult patients comparing curcumin and placebo was performed in Cipto Mangunkusumo General Hospital and Jakarta Heart Center within April and June 2015. Either curcumin (45 mg/day) or placebo was given 7 days prior to PCI until 2 days after PCI. Inflammatory markers (high-sensitivity C-reactive protein [hsCRP] and soluble CD40 ligand [sCD40L]) were measured in three phases (7 days prior PCI, 24 hours post-PCI, and 48 hours post-PCI). There were no significant differences in the reduction of hsCRP and sCD40L between curcumin and placebo groups in three phases of measurement. Curcumin significantly reduce the serum hsCRP (p = 0.006) and sCD40L (p = 0.002) 7 days before PCI to 48 hours post-PCI. The decrement of hsCRP (-14.2% vs.-7.4%) and sCD40L (-24.3% vs.-13.2%) from 24 to 48 hours post-PCI was higher in the curcumin group than placebo group. The administration of curcumin 45 mg dose daily for 7 days prior PCI until 48 hours post-PCI is useful in reducing inflammatory response post-PCI with stable CHD. © 2021 Georg Thieme Verlag. All rights reserved.
curcumin; inflammatory response; PCI; stable CHD
Thieme Medical Publishers, Inc.
10611711
Article
Q3
234
16828